Aktienanalyse zu Clinuvel Pharmaceuticals Limited American Depositary Shares (CUVL)CUVLClinuvel Pharmaceuticals Limited American Depositary Shares

Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the United States of America, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). It has operations in Europe, Singapore, and the United States of America. It develops and manufactures NEURACTHEL (adrenocorticotropic hormone) in different formulations, to target neurological, endocrinological, and degenerative disorders. Its pharmaceutical product, PRENUMBRA, has been developed, and its use is to be expanded in the clinic from stroke to Parkinson's. It operates in the Healthcare sector.

Clinuvel Pharmaceuticals Ltd (CUVL) is currently not a strong buy. The stock is trading at $4.91, which is significantly below its 52-week high of $8.20, indicating a potential for recovery but also a risk of further decline. The RSI is at 29.692, suggesting it is oversold, but the forward P/E ratio is 12.00, which is reasonable, yet the stock has a 20-day change of -14.46%, indicating recent poor performance.